Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy and paste it into your browser)

2. Click "Register"

3. On the registration form, enter your information then click "Submit"

Once the host approves your registration, you will receive a confirmation email containing instructions on how to join the event (event number and password) on the day of the announcement.

Once logged on, you will also be required to connect to a teleconference in order to participate in the live Q&A session with panelists at the end of the event.

Teleconference dial in number (toll-free):

1) To obtain your teleconference number, register first by following the instructions above.

2) Once connected, a pop-up window will appear

3) Select country of affiliation to obtain local dial-in number

4) Dial-in and enter your login details using the provided number within the pop-up window

Please ensure you log on to the event 15 minutes before the start time so as not to miss valuable information.

IMPORTANT NOTICE:

This event is not part of the official Scientific Sessions 2008 as planned by the AHA Committee on Scientific Sessions Programming


'/>"/>
SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):